<DOC>
	<DOCNO>NCT00671567</DOCNO>
	<brief_summary>The purpose study determine safety efficacy Ramelteon , daily ( QD ) , adult subject chronic insomnia .</brief_summary>
	<brief_title>Ramelteon Adults With Chronic Insomnia</brief_title>
	<detailed_description>Insomnia characterize difficulty initiate maintain sleep complaint nonrestorative non-refreshing sleep . Transient insomnia affect approximately one-third one-half US population , base result 2 survey representative sample adult US population conduct Gallup Organization respondent ask `` ever difficulty sleep . '' Based report `` regular '' `` frequent '' sleep difficulty , result study suggest approximately one-tenth US population experience chronic insomnia . The ideal treatment insomnia would reduce latency onset sleep increase total sleep time , without negative impact sleep architecture without safety concern next-day effect . Ramelteon melatonin-1 receptor agonist global development Takeda Chemical Industries , Ltd , treatment transient chronic insomnia treatment Circadian Rhythm Sleep Disorders . This study design determine safety efficacy 35-day treatment chronic insomnia Ramelteon , use subjective measure sleep . Total subject participation time study expect approximately 2 month .</detailed_description>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<criteria>Inclusion Criteria Females childbearing potential sexually active must agree use adequate contraception , neither pregnant lactating Screening throughout duration study . Has primary insomnia define Diagnostic Statistical Manual Mental Disorders , Text Revision history daytime complaint ( ) associate disturbed sleep . Subjective sleep latency great equal 45 minute subjective total sleep time le equal 6.5 hour per night least 3 night week leadin period , base subject diary . Habitual bedtime 8:30 PM 12:00 AM . Body mass index 18 34 , inclusive . Exclusion Criteria Known hypersensitivity Ramelteon related compound , include melatonin . Previously participate study involve Ramelteon . Participated investigational study , and/or take investigational drug within 30 day five halflives prior first day singleblind study medication , whichever longer . Sleep schedule change require employment ( eg , shift worker ) within three month prior first day singleblind study medication , fly across great three time zone within seven day prior screen . Participated weight loss program substantially alter exercise routine within 30 day prior first day singleblind study medication . Has ever history seizure , sleep apnea , chronic obstructive pulmonary disease , restless leg syndrome , schizophrenia , bipolar disorder , mental retardation , cognitive disorder . History psychiatric disorder ( include anxiety depression ) within past 12 month . History drug addiction drug abuse within past 12 month . History alcohol abuse within past 12 month . Current significant neurological , hepatic , renal , endocrine , cardiovascular , gastrointestinal , pulmonary , hematologic metabolic disease unless currently control stable protocolallowed medication 30 day prior first day singleblind study medication . Uses tobacco product nightly awakening . Any clinically important abnormal finding determine medical history , physical examination , electrocardiogram , clinical laboratory test , determine investigator . Positive hepatitis panel . Any additional condition Investigator 's opinion would : Affect sleepwake function Prohibit subject complete study Not best interest subject . Is required take continue take disallow medication , prescription medication , herbal treatment overthe counter medication may interfere evaluation study medication , include : melatonin drug supplement know affect sleep/wake function . anxiolytic hypnotic antidepressant anticonvulsant sedate H1 antihistamine systemic steroid respiratory stimulant decongestant overthecounter prescription stimulant overthecounter prescription diet aids central nervous system active drug ( include herbal preparation central nervous system effect ) narcotic analgesic beta blocker melatonin St. John 's Wort kavakava gingko biloba</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Sleep Disorder</keyword>
	<keyword>Insomnia</keyword>
</DOC>